Boston, MA, May 6, 2015 - Soricimed Biopharma Inc., a private clinical stage company developing novel cancer therapeutics and diagnostics, is presenting a poster entitled SOR-C13, a novel cancer peptide therapeutic targeting the TRPV6 oncochannel shows efficacy in breast and ovarian cancer xenografts in a murine model at PEGS, the essential protein engineering summit, today in Boston.
Validation of new therapeutic targets in oncology has become more urgent in this era of tumor-targeted drugs. TRPV6, a membrane calcium channel that is over-expressed in epithelial cancers such as breast, prostate, ovarian, lung and pancreatic among others, has been suggested as a drugable target for many years but suitable inhibitors have not been available. Soricimed’s SOR-C13 is the first oncology therapeutic drug antagonistic to TRPV6 and is currently being studied within a Phase I clinical trial.
Soricimed’s pre-clinical data presented in the PEGS poster show that targeting TRPV6 with SOR-C13 results in reduced tumor growth in breast and ovarian xenografts in mice. Treatment with SOR-C13 inhibited tumor growth compared to controls and demonstrated similar efficacy to positive controls treated with anti-cancer drugs paclitaxel and CAT - carboplatin plus paclitaxel. Combinations of SOR-C13 plus paclitaxel (for breast) and SOR-C13 plus CAT (for ovarian) showed improved efficacy over the standard drug used alone.
“These results support the clinical development of SOR-C13 as an anti-cancer therapeutic”, stated Professor Jack Stewart, Chief Scientific Officer, Soricimed Biopharma Inc. “We can conclude that TRPV6 is a viable oncology target in epithelial tumors since its inhibition results in tumor growth suppression in these two models.”
Soricimed’s Phase I trial of Soricimed’s first-in-class TRPV6-targeting drug, SOR-C13, will be concluded by the end of 2015.
Soricimed Biopharma Inc., a private Canadian clinical stage company developing novel cancer therapeutics and diagnostics, was created in 2005 by Professor Jack Stewart and Paul Gunn following the discovery and development of a proprietary peptide, soricidin. Soricidin derivatives are the basis for Soricimed Biopharma Inc.’s targeted cancer management program focused on cancer therapeutics and diagnostics. Using focused innovative strategies in collaboration with major world-class cancer research institutions, Soricimed’s drugs have demonstrated a capability to reduce cancer cell viability, induce apoptosis and to reduce human tumour volume while minimizing side-effects in various classic animal and in vitro tumour models. Privately held, Soricimed is funded through private investors and various programs from the Government of Canada. For more information please visit, www.soricimed.com.
Julie Fotheringham - Partner, Hageman Communications